MedTrace Logo

Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea

NCT02043145 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 727

Last updated 2014-06-13

Study results available
· View outcomes & findings →

Summary

This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines in clinical practice.

Conditions

  • Hyperhidrosis
  • Muscle Spasticity
  • Glabellar Lines

Interventions

BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02043145 on ClinicalTrials.gov